Vertex Pharmaceuticals, VRTX

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price
Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.12% to 5,842.63 and the Dow Jones Industrial Average DJIA rising 1.14% to 43,006.59.
Vertex Pharmaceuticals Incorporated (VRTX): Among Renaissance Technologies Portfolio’s Top Stock Picks
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other Renaissance Technologies portfolio’s top stock picks.
TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Zacks Investment Research on MSN3h
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
Editas Medicine EDIT reported a loss of 55 cents per share in the fourth quarter of 2024, wider than the Zacks Consensus ...
Zacks Research Issues Pessimistic Outlook for VRTX Earnings
Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...
Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript)
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
Morningstar10d
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Nasdaq7d
VRTX April 11th Options Begin Trading
Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options become available today, for the April 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...
Vertex Pharma wins EU backing to expand label for Kaftrio cystic fibrosis drug
Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...
Vertex shares down after Stifel downgrades stock to hold
Inc to “Hold” from “Buy” and lowered its price target to $31 from $35, over the company’s investment strategy and valuation. While Vertex reported solid quarterly, Stifel noted its plan to accelerate ...